Most Read Articles
01 Oct 2015
BLACKMORES VITAMIN D3 – Vitamin D3 1,000 IU Capsules
15 Dec 2016
New drug applications approved by US FDA as of 1 - 15 December 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Kavitha G. Shekar, 21 Jun 2016

The American Diabetes Association’s (ADA) President Desmond Schatz challenged the scientific community to transform diabetes from an invisible disease to a highly visible crisis. “Diabetes is an epidemic spiralling out of control across this country and around the world, yet it remains largely invisible,” he said, speaking at the 76th Scientific Sessions of ADA in New Orleans, Louisiana, US.

31 Jul 2017
New drug applications approved by US FDA as of 16 - 31 July 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

T2D ups mortality after coronary artery bypass surgery

14 Jul 2017

Type 2 diabetes mellitus (T2DM) patients have a significantly higher mortality rate following coronary artery bypass surgery (CABG) compared with those without T2DM, according to a new meta-analysis.

A meta-analysis of 11 studies (n=12,965 patients) that investigated mortality after CABG in human participants with and without T2DM found that mortality was significantly higher in T2DM patients (odds ratio [OR], 1.54; 95 percent CI, 1.37 to 1.72; p<0.00001) over a follow up of 1 to 15 years.

Results remained consistent even when considering follow-up periods of 5 to 15 (OR, 1.53; 1.36 to 1.72; p<0.00001) and 7 to 15 (OR, 1.53; 1.26 to 1.87; p<0.0001) years.

Subtype analysis with respect to type of death showed that both all-cause mortality (OR, 1.34; 1.12 to 1.60; p=0.001) and cardiac death (OR, 1.62; 1.31 to 2.00; p<0.00001) was significantly higher in T2DM patients.

Further analysis showed that short-term (1 to 5 years; OR, 1.65; 1.07 to 2.54; p=0.02), middle-term (5 to 7 years; OR, 1.53; 1.32 to 1.76; p<0.00001) and long-term mortality (7 to 15 years; OR, 1.53; 1.26 to 1.87; p<0.0001) were all significantly greater in T2DM patients.

In contrast, other adverse cardiovascular outcomes, such as myocardial infarction (OR, 1.15; 0.81 to 1.64; p=0.44), repeated revascularization (OR, 1.09; 0.88 to 1.36; p=0.43) and stroke (OR, 1.69; 0.93 to 3.07; p=0.08) were not significantly more common in T2DM patients.

The meta-analysis was performed on six randomized controlled trials (RCTs) and five observational studies retrieved from Medline, the Cochrane Library and Embase. Those with follow-up periods of <1 year, that did not report on mortality or that did not include control were excluded.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 Oct 2015
BLACKMORES VITAMIN D3 – Vitamin D3 1,000 IU Capsules
15 Dec 2016
New drug applications approved by US FDA as of 1 - 15 December 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Kavitha G. Shekar, 21 Jun 2016

The American Diabetes Association’s (ADA) President Desmond Schatz challenged the scientific community to transform diabetes from an invisible disease to a highly visible crisis. “Diabetes is an epidemic spiralling out of control across this country and around the world, yet it remains largely invisible,” he said, speaking at the 76th Scientific Sessions of ADA in New Orleans, Louisiana, US.

31 Jul 2017
New drug applications approved by US FDA as of 16 - 31 July 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.